Talaris Therapeutics Correlations
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
The current 90-days correlation between Talaris Therapeutics and Adicet Bio is -0.22 (i.e., Very good diversification). The correlation of Talaris Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Talaris Therapeutics Correlation With Market
Significant diversification
The correlation between Talaris Therapeutics and DJI is 0.06 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Talaris Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Talaris |
Moving together with Talaris Stock
Moving against Talaris Stock
| 0.49 | BKRKY | Bank Rakyat | PairCorr |
| 0.48 | PPERY | Bank Mandiri Persero | PairCorr |
| 0.48 | BKRKF | PT Bank Rakyat | PairCorr |
| 0.48 | PTBRY | Bank Negara Indonesia | PairCorr |
| 0.47 | SHG | Shinhan Financial | PairCorr |
| 0.45 | PBCRY | Bank Central Asia | PairCorr |
| 0.44 | PBCRF | PT Bank Central | PairCorr |
| 0.43 | PPERF | Bank Mandiri Persero | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Talaris Stock performing well and Talaris Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Talaris Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EWTX | 2.59 | 0.10 | 0.03 | 0.11 | 3.28 | 6.44 | 26.07 | |||
| ACET | 3.05 | (0.72) | 0.00 | (0.70) | 0.00 | 6.19 | 23.81 | |||
| CGEM | 2.93 | (0.65) | 0.00 | (0.27) | 0.00 | 5.94 | 17.85 | |||
| VOR | 3.88 | (0.02) | 0.00 | 0.01 | 3.87 | 8.11 | 36.01 | |||
| CTMX | 3.09 | (0.07) | 0.00 | (0.02) | 0.00 | 6.78 | 22.92 | |||
| TIL | 5.70 | (1.40) | 0.00 | (0.52) | 0.00 | 12.77 | 30.36 | |||
| NLTX | 2.25 | (0.18) | 0.00 | (0.88) | 0.00 | 4.05 | 27.84 | |||
| SPRO | 1.92 | (0.51) | 0.00 | (1.16) | 0.00 | 3.45 | 14.92 | |||
| ASMB | 3.32 | (0.20) | 0.00 | (0.30) | 0.00 | 8.88 | 21.34 | |||
| NUVB | 3.55 | (0.12) | 0.00 | (0.01) | 0.00 | 9.48 | 21.30 |
Talaris Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Talaris Therapeutics stock to make a market-neutral strategy. Peer analysis of Talaris Therapeutics could also be used in its relative valuation, which is a method of valuing Talaris Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Talaris Therapeutics Corporate Management
| Nancy MD | Chief Officer | Profile | |
| Eric Gornstein | Head Planning | Profile | |
| Suzanne Tollerud | VP Devel | Profile | |
| Michael Zdanowski | Chief Officer | Profile | |
| JD LLB | CEO and President | Profile | |
| Suzanne MD | Member Founder | Profile | |
| Mary Fenton | CFO Treasurer | Profile |
Still Interested in Talaris Therapeutics?
Investing in delisted delisted stocks can be risky, as the stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.